Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Xeris Pharmaceuticals Inc(XERS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for XERS
09/25/2026: XERS (5-star) is currently NOT-A-BUY. Pass it for now.
Xeris Pharmaceuticals is a commercial-stage biotechnology company that leverages proprietary formulation technology to improve injectable drug delivery for diabetes and rare endocrine conditions. The company's strengths include a growing portfolio of approved products like Gvoke and Recorlev, which provide a foundation for revenue expansion. Its primary investment story hinges on successfully scaling these commercial products and licensing its technology platforms. However, investors must consider risks such as operating losses, high competition in specialty markets, and the need for ongoing capital. This stock may suit growth-oriented investors with a high risk tolerance who are interested in the evolution of specialty pharmaceutical companies and their future milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Xeris represents a commercial-stage growth opportunity in the specialty pharma space. |
| Momentum investor | Mixed fit | Momentum is conditional on positive commercial sales data and clinical news flow. |
| Value investor | Weak fit | The company has limited valuation support from earnings, making it a poor fit for traditional value strategies. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital. |
| Low-risk investor | Weak fit | Biotech volatility and execution risks make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience significant price swings based on news flow. |
| Valuation risk | Medium / high | Growth expectations are often priced into the stock, leaving little margin for error. |
| Competition risk (specialty pharma) | High | Established players can outspend Xeris in marketing and market access. |
| Business quality | Medium | The company is evolving but faces ongoing profitability challenges. |
| Dividend income | Low / none | Income investors should not look here for yield. |
| Execution risk | Medium / high | Success depends on sales performance and cost management. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 101.69% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.66B USD | Price to earnings Ratio - | 1Y Target Price 12.29 |
Price to earnings Ratio - | 1Y Target Price 12.29 | ||
Volume (30-day avg) 1.8M shares | Beta 0.85 | 52 Weeks Range 5.25 - 10.08 | Updated Date 09/27/2026 |
52 Weeks Range 5.25 - 10.08 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Pharmaceuticals | Revenue from the sale of Gvoke, Keveyis, and Recorlev. | Xeris makes most of its money from selling its approved medications for endocrine and metabolic diseases. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 36.9 | Enterprise Value 1.75B | Price to Sales(TTM) 4.95 |
Enterprise Value 1.75B | Price to Sales(TTM) 4.95 | ||
Enterprise Value to Revenue 5.21 | Enterprise Value to EBITDA 73.14 | Shares Outstanding 182.32M | Shares Floating 176.00M |
Shares Outstanding 182.32M | Shares Floating 176.00M | ||
Percent Insiders 3.06 | Percent Institutions 60.11 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Xeris Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Chicago, IL, United States | ||
IPO Launch date 2018-06-21 | Chairman & CEO Mr. John P. Shannon | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 435 | Website https://www.xerispharma.com |
Full time employees 435 | Website https://www.xerispharma.com | ||
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.